RNAC Stock Analysis: Buy, Sell, or Hold?
RNAC - Cartesian Therapeutics, Inc. Common Stock
$6.83
-0.15 (-2.15%)
▼
5d:
-10.6%
30d:
-1.59%
90d:
-16.71%
WAIT
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 12, 2026
Get Alerted When RNAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: RNAC is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: RNAC is down 10.6% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: RNAC is currently trading at $6.83, which is considered oversold relative to its 30-day fair value range of $6.85 to $7.73.
Technical Outlook: Technically, RNAC is in a strong downtrend. The price is currently testing key support at $6.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.57 (+420.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RNAC is in a strong downtrend. The price is currently testing key support at $6.74. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $35.57 (+420.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$6.85 -
$7.73
Company Quality Score
52/100
(HOLD)
Options IV Signal
50th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
80.0%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 50th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 420.8% below Wall St target ($35.57)
- WARNING: Recommendation downgraded due to -10.6% 5-day decline - wait for stabilization
Fair Price Analysis
30-Day Fair Range
$6.85 -
$7.73
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$0.96
(14.1%)
Support & Resistance Levels
Support Level
$6.74
Resistance Level
$7.89
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
-2.65
Wall Street Target
$35.57
(+420.8%)
Revenue Growth (YoY)
16.8%
Earnings Growth (YoY)
-7.4%
Last updated: February 01, 2026 9:42 PM ET
Data refreshes hourly during market hours. Next update: 10:42 PM
Data refreshes hourly during market hours. Next update: 10:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RNAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$215 | 60 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$89 | 61 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$217 | 53 HOLD |
|
ACAD
ACADIA Pharmaceuticals I… |
BUY
20 analysts |
$31 | 55 HOLD |
|
KURA
Kura Oncology Inc |
STRONG BUY
15 analysts |
$33 | 54 HOLD |
